SAB BIOTHERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Warrant Issued
SAB BIOTHERAPEUTICS, INC. (SABS) reported Adjustments to Additional Paid in Capital, Warrant Issued of $3.83 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2025-03-31
- SAB BIOTHERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-03-31 was $93.53K.
- SAB BIOTHERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-03-31 was $7.03M.
- SAB BIOTHERAPEUTICS, INC. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $3.83M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2023-12-31 | $3.83M 10-K · filed 2025-03-31 | |
| 2023-03-31 | $93.53K 10-Q · filed 2024-11-06 | |
| 2021-03-31 | $7.03M 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |